Drug Profile
Interferon alpha-2a biosimilar - Biolotus
Alternative Names: INTEFEN-IFNLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Biolotus
- Developer Biolotus; Shenyang Sunshine Pharmaceutical
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Interferon alfa 2a stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Condylomata acuminata; Haematological malignancies; Hepatitis B; Hepatitis C; Lymphoma
Most Recent Events
- 19 Jun 2015 Launched for Lymphoma, Hepatitis B, Hepatitis C, Hematological malignancies and Condylomata acuminata in Brazil (IM) (SC)